IL22BP Mediates the Anti-Tumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans
Standard
IL22BP Mediates the Anti-Tumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. / Kempski, Jan; Giannou, Anastasios D; Riecken, Kristoffer; Zhao, Lilan; Steglich, Babett; Lücke, Jöran; Garcia-Perez, Laura; Karstens, Karl-Frederick; Wöstemeier, Anna; Nawrocki, Mikolaj; Pelczar, Penelope; Witkowski, Mario; Nilsson, Sven; Konczalla, Leonie; Shiri, Ahmad Mustafa; Kempska, Joanna; Wahib, Ramez; Brockmann, Leonie; Huber, Philipp; Gnirck, Ann-Christin; Turner, Jan-Eric; Zazara, Dimitra E; Arck, Petra C; Stein, Alexander; Simon, Ronald; Daubmann, Anne; Meiners, Jan; Perez, Daniel; Strowig, Till; Koni, Pandelakis; Kruglov, Andrey A; Sauter, Guido; Izbicki, Jakob R; Guse, Andreas H; Roesch, Thomas; Lohse, Ansgar W; Flavell, Richard A; Gagliani, Nicola; Huber, Samuel.
In: GASTROENTEROLOGY, Vol. 159, No. 4, 10.2020, p. 1417-1430.e3.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - IL22BP Mediates the Anti-Tumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans
AU - Kempski, Jan
AU - Giannou, Anastasios D
AU - Riecken, Kristoffer
AU - Zhao, Lilan
AU - Steglich, Babett
AU - Lücke, Jöran
AU - Garcia-Perez, Laura
AU - Karstens, Karl-Frederick
AU - Wöstemeier, Anna
AU - Nawrocki, Mikolaj
AU - Pelczar, Penelope
AU - Witkowski, Mario
AU - Nilsson, Sven
AU - Konczalla, Leonie
AU - Shiri, Ahmad Mustafa
AU - Kempska, Joanna
AU - Wahib, Ramez
AU - Brockmann, Leonie
AU - Huber, Philipp
AU - Gnirck, Ann-Christin
AU - Turner, Jan-Eric
AU - Zazara, Dimitra E
AU - Arck, Petra C
AU - Stein, Alexander
AU - Simon, Ronald
AU - Daubmann, Anne
AU - Meiners, Jan
AU - Perez, Daniel
AU - Strowig, Till
AU - Koni, Pandelakis
AU - Kruglov, Andrey A
AU - Sauter, Guido
AU - Izbicki, Jakob R
AU - Guse, Andreas H
AU - Roesch, Thomas
AU - Lohse, Ansgar W
AU - Flavell, Richard A
AU - Gagliani, Nicola
AU - Huber, Samuel
N1 - Jöran Lücke ist keine externe Person, sondern Mitarbeiter der I. Med. ZIM
PY - 2020/10
Y1 - 2020/10
N2 - BACKGROUND & AIMS: Unregulated activity of interleukin (IL) 22 promotes intestinal tumorigenesis in mice. IL22 binds the antagonist IL22 subunit alpha 2 (IL22RA2, also called IL22BP). We studied whether alterations in IL22BP contribute to colorectal carcinogenesis in humans and mice.METHODS: We obtained tumor and nontumor tissues from patients with colorectal cancer (CRC) and measured levels of cytokines by quantitative polymerase chain reaction, flow cytometry, and immunohistochemistry. We measured levels of Il22bp messenger RNA in colon tissues from wild-type, Tnf-/-, Lta-/-, and Ltb-/- mice. Mice were given azoxymethane and dextran sodium sulfate to induce colitis and associated cancer or intracecal injections of MC38 tumor cells. Some mice were given inhibitors of lymphotoxin beta receptor (LTBR). Intestine tissues were analyzed by single-cell sequencing to identify cell sources of lymphotoxin. We performed immunohistochemistry analysis of colon tissue microarrays from patients with CRC (1475 tissue cores, contained tumor and nontumor tissues) and correlated levels of IL22BP with patient survival times.RESULTS: Levels of IL22BP were decreased in human colorectal tumors, compared with nontumor tissues, and correlated with levels of lymphotoxin. LTBR signaling was required for expression of IL22BP in colon tissues of mice. Wild-type mice given LTBR inhibitors had an increased tumor burden in both models, but LTBR inhibitors did not increase tumor growth in Il22bp-/- mice. Lymphotoxin directly induced expression of IL22BP in cultured human monocyte-derived dendritic cells via activation of nuclear factor κB. Reduced levels of IL22BP in colorectal tumor tissues were associated with shorter survival times of patients with CRC.CONCLUSIONS: Lymphotoxin signaling regulates expression of IL22BP in colon; levels of IL22BP are reduced in human colorectal tumors, associated with shorter survival times. LTBR signaling regulates expression of IL22BP in colon tumors in mice and cultured human dendritic cells. Patients with colorectal tumors that express low levels of IL22BP might benefit from treatment with an IL22 antagonist.
AB - BACKGROUND & AIMS: Unregulated activity of interleukin (IL) 22 promotes intestinal tumorigenesis in mice. IL22 binds the antagonist IL22 subunit alpha 2 (IL22RA2, also called IL22BP). We studied whether alterations in IL22BP contribute to colorectal carcinogenesis in humans and mice.METHODS: We obtained tumor and nontumor tissues from patients with colorectal cancer (CRC) and measured levels of cytokines by quantitative polymerase chain reaction, flow cytometry, and immunohistochemistry. We measured levels of Il22bp messenger RNA in colon tissues from wild-type, Tnf-/-, Lta-/-, and Ltb-/- mice. Mice were given azoxymethane and dextran sodium sulfate to induce colitis and associated cancer or intracecal injections of MC38 tumor cells. Some mice were given inhibitors of lymphotoxin beta receptor (LTBR). Intestine tissues were analyzed by single-cell sequencing to identify cell sources of lymphotoxin. We performed immunohistochemistry analysis of colon tissue microarrays from patients with CRC (1475 tissue cores, contained tumor and nontumor tissues) and correlated levels of IL22BP with patient survival times.RESULTS: Levels of IL22BP were decreased in human colorectal tumors, compared with nontumor tissues, and correlated with levels of lymphotoxin. LTBR signaling was required for expression of IL22BP in colon tissues of mice. Wild-type mice given LTBR inhibitors had an increased tumor burden in both models, but LTBR inhibitors did not increase tumor growth in Il22bp-/- mice. Lymphotoxin directly induced expression of IL22BP in cultured human monocyte-derived dendritic cells via activation of nuclear factor κB. Reduced levels of IL22BP in colorectal tumor tissues were associated with shorter survival times of patients with CRC.CONCLUSIONS: Lymphotoxin signaling regulates expression of IL22BP in colon; levels of IL22BP are reduced in human colorectal tumors, associated with shorter survival times. LTBR signaling regulates expression of IL22BP in colon tumors in mice and cultured human dendritic cells. Patients with colorectal tumors that express low levels of IL22BP might benefit from treatment with an IL22 antagonist.
U2 - 10.1053/j.gastro.2020.06.033
DO - 10.1053/j.gastro.2020.06.033
M3 - SCORING: Journal article
C2 - 32585307
VL - 159
SP - 1417-1430.e3
JO - GASTROENTEROLOGY
JF - GASTROENTEROLOGY
SN - 0016-5085
IS - 4
ER -